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Abstract
Background: Nicotine plays an important role in cigarette-smoke-associated airway disease. The present study was
designed to examine if nicotine could induce airway hyperresponsiveness through kinin receptors, and if so,
explore the underlying mechanisms involved.
Methods: Murine tracheal segments were cultured for 1, 2 or 4 days in serum-free DMEM medium in presence of
nicotine (1 and 10 μM) or vehicle (DMSO). Contractile responses induced by kinin B1 receptor agonist, des-Arg
9-
bradykinin, and B2 receptor agonist, bradykinin, were monitored with myographs. The B1 and B2 receptor mRNA
expressions were semi-quantified using real-time PCR and their corresponding protein expressions assessed with
confocal-microscopy-based immunohistochemistry. Various pharmacological inhibitors were used for studying
intracellular signaling pathways.
Results: Four days of organ culture with nicotine concentration-dependently increased kinin B1 and B2 receptor-
mediated airway contractions, without altering the kinin receptor-mediated relaxations. No such increase was seen
at day 1 or day 2. The airway contractile responses to 5-HT, acetylcholine and endothelin receptor agonists
remained unaffected by nicotine. Two different neuronal nicotinic receptor antagonists MG624 and
hexamethonium blocked the nicotine-induced effects. The enhanced contractile responses were accompanied by
increased mRNA and protein expression for both kinin receptors, suggesting the involvement of transcriptional
mechanisms. Confocal-microscopy-based immunohistochemistry showed that 4 days of nicotine treatment induced
activation (phosphorylation) of c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase 1 and 2
(ERK1/2) and p38. Inhibition of JNK with its specific inhibitor SP600125 abolished the nicotine-induced effects on
kinin receptor-mediated contractions and reverted the enhanced receptor mRNA expression. Administration of
phosphodiesterase inhibitors (YM976 and theophylline), glucocorticoid (dexamethasone) or adenylcyclase activator
(forskolin) suppressed the nicotine-enhanced airway contractile response to des-Arg
9-bradykinin and bradykinin.
Conclusions: Nicotine induces airway hyperresponsiveness via transcriptional up-regulation of airway kinin B1 and
B2 receptors, an effect mediated via neuronal nicotinic receptors. The underlying molecular mechanisms involve
activation of JNK- and PDE4-mediated intracellular inflammatory signal pathways. Our results might be relevant to
active and passive smokers suffering from airway hyperresponsiveness, and suggest new therapeutic targets for the
treatment of smoke-associated airway disease.
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Airway hyperreactivity is a major feature of asthma and
a consequence of airway inflammation. It is well-known
that both active [1,2] and passive cigarette smoke expo-
sure [3,4] can cause airway hyperresponsiveness (AHR).
Maternal cigarette smoking increases the risk for wheez-
ing in early life and the development of childhood
asthma [5,6]. Second-hand smoke exposure in asth-
matics is associated with poor asthma control, greater
asthma severity and greater risk of asthma-related hospi-
tal admission [7]. In vivo studies in guinea pigs have
demonstrated that chronic exposure to tobacco smoke
selectively increases airway reactivity to bradykinin and
capsaicin, without altering responses to methacholine or
histamine [8]. This suggests an important role for brady-
kinin in tobacco smoke-induced AHR.
Tobacco smoke is a composite of irritant molecules,
including nicotine, acetaldehyde, formaldehyde, nitrogen
oxides, and heavy metals, and long-term exposure
results in chronic airway inflammation, AHR and in
some individuals, chronic obstructive pulmonary disease
(COPD). Nicotine is one of the more important compo-
nents of cigarette smoke. It is also widely marketed as
an aid to smoke cessation in forms of nicotine-replace-
ment products. Once inhaled, nicotine is quickly taken
up by the bloodstream and distributed throughout the
body, to act primarily on nicotinic acetylcholine recep-
tors. In humans, functional nicotinic receptors, of both
the muscle and neuronal subtypes, are present on fibro-
blasts and in bronchial epithelial cells. They have the
ability to activate protein kinase C as well as members
of the mitogen-activated protein kinases (MAPKs)
including extracellular signal-regulated kinase 1 and 2
(ERK1/2) and p38 [9]. Many of the detrimental health
effects of cigarette-smoke are believed to be due to nico-
tine’s ability to affect the immune system. Stimulation of
the nicotinic receptor produces complex reactions
including both inflammatory [10] and anti-inflammatory
effects [11], including modulation of allergic responses
[12]. There is also evidence suggesting that nicotine can
directly interfere with the phosphorylation of intracellu-
lar inflammatory signal molecules such as c-Jun N-term-
inal kinase (JNK) and ERK1/2, without involvement of
the nicotinic receptors [13]. However, the knowledge
about the intracellular mechanisms behind nicotine’s
effects is still limited.
Inhibition of phosphodiesterases (PDEs) results in the
elevation of cyclic AMP (cAMP) and cyclic GMP
(cGMP) which lead to a variety of cellular effects includ-
ing airway smooth muscle relaxation and inhibition of
cellular inflammation [14]. The archetypal non-selective
PDE inhibitor theophylline shows anti-inflammatory
properties and has been used clinically for more than 70
years. However, its narrow therapeutic window and
extensive interactions with other drugs limits its clinical
use. PDE4 is specific for the break-down of intracellular
cAMP and PDE4 inhibitors have been intensely investi-
gated for the treatment of asthma and COPD. The
PDE4 subtype PDE4D5 has been recently shown to be
the key physiological regulator of beta-adrenergic recep-
tor-induced cAMP turnover within human airway
smooth muscle [15]. It is well-known that cells respond
to stimuli through a “network” of different signaling
pathways. Interestingly, the cAMP pathway can interact
with the MAPK cascade. cAMP negatively regulates
MAPK p38 activation, and thereby contributing to
tumor necrosis factor (TNF)-a-induced apoptosis in cer-
tain cell types [16]. Activation of ERK5 and the subse-
quent transcription of c-JUN, but not ERK1/2, can be
blocked by cAMP through cAMP-dependent protein
kinase (PKA) [17].
Airway G-protein coupled receptors (GPCR), such as
kinin, 5-hydroxytryptamine (5-HT), endothelin and
muscarinic acetylcholine receptors, not only mediate air-
way smooth muscle contraction, but also airway inflam-
mation and remodelling [18]. We have previously, by
using an in vitro model of chronic airway inflammation,
demonstrated that cytokines can induce transcriptional
up-regulation of kinin B1 and B2 receptors and subse-
quently increase kinin receptor-mediated contractions
[19]. Our receptor characterization studies using specific
pharmacological antagonists have demonstrated that the
B1 receptor is selectively activated by des-Arg
9-bradyki-
nin, whereas the B2 receptor is activated by bradykinin
[20]. The B2 receptor is constitutively expressed in air-
ways, while the B1 receptor is inducible following tissue
injury and inflammation [21]. Stimulation of the kinin
receptors in airways causes both bronchoconstriction
and epithelium-dependent relaxation, as well as mucus
secretion, edema and cough. The relaxation is mediated
via activation of cyclooxygenase (COX) and release of
the bronchodilator prostaglandin E2 (PGE2) [21]. The
mechanism behind AHR to kinins appears to involve
activation of intracellular MAPKs and the down-stream
transcription factor nuclear factor-kappaB (NF-B)
[20,22].
One of the hypotheses of the present study is that
long-term exposure to nicotine can induce activation of
airway MAPK-mediated inflammatory signal pathways
and subsequently cause AHR via up-regulation of kinin
receptors. This idea is based on previous data revealing
activation of MAPK-mediated NF-B inflammatory sig-
nal pathways in AHR along with an up-regulation of
kinin receptors [20,22,23]. This is further corroborated
by in vivo studies showing selective up-regulation of
kinin receptors after exposure to cigarette smoke [8]
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human bronchial cells following stimulation of nicotinic
receptors [9].
Reports of a role for PDE4 inhibitors in asthma and
COPD treatment [14] together with the known interac-
tions between the MAPK and cAMP pathways [16,17]
lead to our interest for possible nicotine-induced
changes in PDE4 and cAMP pathway. Thus, the present
study was designed to investigate if long-term exposure
to nicotine could induce AHR to bradykinin and des-
Arg
9-bradykinin through the selective up-regulation of
kinin receptors and to explore the underlying intracellu-
lar inflammatory signal transduction mechanisms
involved, with focus on both MAPK and PDE4.
Materials and methods
Tissue preparation
Male BALB/c J mice (9-10 weeks old) were sacrificed by
cervical dislocation. The whole trachea was rapidly
removed and placed into cold Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM; 4500 mg L
-1 D-glucose, 110
mg L
-1 sodium pyruvate, 584 mg L
-1 L-glutamine). For
in vitro pharmacology and immunohistochemistry stu-
dies, the trachea was cut into ring segments, each con-
taining three cartilage rings, while the whole trachea
was kept intact for real-time PCR studies. The experi-
mental protocol was approved by the local Ethics
Committee.
Organ culture
The tracheal rings, alternatively the whole trachea, were
placed individually in wells of a 96- or 24-well plate
(Ultra-low attachment; Sigma, St. Louis, MO, U.S.A.)
with 300 μL or 1 mL serum-free DMEM culture med-
ium supplemented with penicillin (100 U mL
-1)a n d
streptomycin (100 μgm L
-1). All tissue were incubated at
37°C in humidified 5% CO2 in air with either nicotine (1
or 10 μM), vehicle (dimethyl sulfoxide, DMSO, 0.1%) or
nicotine (10 μM) plus various inhibitors for 1, 2 or 4
days. The segments were transferred to new wells con-
taining fresh medium with supplements of nicotine,
vehicle or inhibitors every day.
In-vitro pharmacology
The cultured tracheal ring was immersed in tempera-
ture-controlled (37°C) myograph bath (Organ Bath
M o d e l7 0 0M O ,J . P .T r a d i n g ,A a r h u s ,D e n m a r k )c o n -
taining 5 ml Krebs-Henseleit buffer solution (143 mM
Na
+, 5.9 mM K
+,1 . 5m MC a
2+, 2.5 mM Mg
2+,1 2 8m M
Cl
-,1 . 2m MH 2PO4
2-,1 . 2m MS O 4
2-,2 5m MH C O
3-
and 10 mM D-glucose), continuously equilibrated with
5% CO2 in 95% O2 at a pH of 7.4. Each tracheal seg-
ment was mounted on two L-shaped metal prongs. One
of the prongs was connected to a force-displacement
transducer for continuous recording of isometric tension
by Chart software (ADInstruments Ltd, Hastings, U.K.),
while the other prong was a displacement device, allow-
ing gentle stretching of the tracheal rings mounted. A
basal tension of 0.8 mN was gradually reached over the
course of at least 90 min. The segment viabilities were
tested using 60 mM KCl. KCl was later washed out with
Kreb-Henseleit buffer solution for three times until the
segments reached basal tension. Thereafter, each seg-
ment was incubated with 3 μM indomethacin for 30
min before administration of agonists to inhibit epithe-
lium-dependent relaxations. Agonists were then admi-
nistered cumulatively to produce their concentration-
effect curves. To test their relaxant properties, segments
were first pre-constricted with 1 μMc a r b a c h o l ,a n d
after reaching stable plateaus, the concentration-effect
curves for bradykinin- and des-Arg
9-bradykinin-induced
relaxations were produced in the absence of
indomethacin.
Real-time quantitative PCR
After homogenization of the tissues, the total RNA was
extracted using the RNeasy Mini kit following the sup-
plier’s instructions (QIAGEN GmbH, Hilden, Germany).
The purity of total RNA was checked with a spectro-
photometer and the wavelength absorption ratio (260/
280 nm) was between 1.7 and 2.0 in all preparations.
Reverse transcription of total RNA (0.3-0.4 μg) to cDNA
was carried out using Omniscript™ reverse transcriptase
kit (QIAGEN GmbH, Hilden, Germany) in 20 μl volume
reaction at 37°C for 1 h using Mastercycler personal
PCR machine (Eppendorf AG, Hamburg, Germany).
Specific primers for murine kinin B1 and B2 receptors,
and the house keeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were designed using Prime
Express 2.0 software (Applied Biosystem, Forster city,
CA, USA) and synthesized with DNA Technology A/S
(Aarhus, Denmark). The sequences are as following:
Kinin B1 receptor [Accession Number: NM_007539]:
Forward: 5’-CCA TAG CAG AAA TCT ACC TGG
CTA AC-3’; Reverse: 5’-GCC AGT TGA AAC GGT
TCC-3’
Kinin B2 receptor [Accession Number: NM_009747]:
Forward: 5’-ATG TTC AAC GTC ACC ACA CAA GTC-
3’;R e v e r s e :5 ’-TGG ATG GCA TTG AGC CAA C-3’
GAPDH [Accession Number: XM_001473623]: For-
ward: 5’-CAT GGC CTT CCG TGT TCC TA-3’;
Reverse: 5’-TGC TTC ACC ACC TTC TTG ATG-3’
Real-time PCR was performed with QuantiTect™
SYBR® Green PCR kit (QIAGEN GmbH, Hilden, Ger-
many) in the Smart Cycler® II system (Cepheid, Sunny-
vale, CA, USA). The system automatically monitors the
b i n d i n go faf l u o r e s c e n td y eS Y B R ®G r e e nt od o u b l e -
stranded DNA during each cycle of PCR amplification.
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volumes and carried out with heating 95°C for 15 min
followed by touchdown PCR i.e. denature at 94°C for 30
sec and annealing at 66°C for 1 min for the first PCR
cycle, thereafter, a 2°C decrease for the annealing tem-
perature in every cycle until 56°C. Finally, 40 thermal
cycles with 94°C for 30 sec and 55°C for 1 min were
performed. The data were analyzed with the threshold
cycle (CT) method and the specificity of the PCR pro-
ducts was checked by the dissociation curves. A blank
(no template) was included in all the experiments as
negative control. The relative amount of mRNA was
expressed as the CT values of mRNA for kinin B1 or B2
receptor in relation to the CT values for the house-keep-
ing gene GAPDH in the same sample.
Immunohistochemistry with confocal microscopy
After organ culture, the tracheal segments were
immersed in a fixative solution consisting of 4% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.4) for 3 h
at 4°C. After fixation, the specimens were dehydrated in
20% sucrose in 0.1 M phosphate buffer (pH 7.4) for 24
h at 4°C, then frozen in Tissue-Tek (Sakura Finetek Eur-
ope B.V., Zoeterwoude, Netherlands) and stored at -80°
C. Sections were cut to 10-μm-thick slices in a cryostat
and mounted on SuperFrost Plus slides (Menzel GMBH
& COKG, Braunschweig, Germany).
Immunohistochemistry were carried out using stan-
dard protocols, i.e. the sections were incubated with the
p r i m a r ya n t i b o d yo v e r n i g h ta t4 ° Ca n dt h es e c o n d a r y
antibody for 1 h at room temperature in darkness. Pri-
mary and secondary antibodies as well as the dilutions
used were as following: kinin B1 receptor (1:50, goat,
Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA),
kinin B2 receptor (1:100, rabbit, Alexis Biochemical,
Lausen, Switzerland), phospho-SAPK/JNK (Thr183/
Tyr185) (1:50, rabbit, Cell Signalling Technology, Inc.
Beverly, MA, USA), phospho-p38 MAPK (Thr180/
Tyr182) (1:100, rabbit, Cell Signalling Technology) and
phospho-ERK1/2 MAPK (Thr202/Tyr204) (1:100, rabbit,
Cell Signalling Technology). The appropriate secondary
antibodies, goat anti-rabbit IgG H&L conjugated to
fluorescein isothiocynate (FITC) or Texas Red or Alexa
Fluor® 488 donkey anti-goat IgG H&L was used for
fluorescence microscopic imaging, respectively. In the
control experiments, either the primary antibody or the
secondary antibody was omitted. The stained specimens
were examined under a confocal microscope (Nikon,
C1plus, Nikon Instruments Inc., NY, USA). The fluores-
cence intensity was measured and analysed by Image J
software http://rsb.info.nih.gov/ij.
To avoid systemic errors, the nicotine-treated speci-
men and the corresponding control are always cultured,
fixated, stained, examined and scanned at the same time
as the same batch, and the setting of the confocal
microscope is kept unchanged throughout. This ensures
comparability between the groups. The measurements
are repeated for each specimen at 6 preset randomly
selected sections, at each section the florescence density
was measured at 6 areas, and the mean florescence den-
sity was obtained from 6 experiments. All measurements
are checked and confirmed by another senior researcher.
Reagents
Bradykinin, des-Arg
9-bradykinin, sarafotoxin 6b and sar-
afotoxin 6c were purchased from Neosystem S.A., Stras-
bourg, France. SP600125 (anthrax(1,9-cd)pyrazol-6(2H)-
one) was from Calbiochem, Bad Soden, Germany. Nico-
tine, dexamethasone, indomethacin, 5-HT, carbachol,
acetylcholine, YM976, theophylline, forskolin, hexam-
ethonium, MG624, DMEM and Krebs-Henseleit buffer
were from Sigma, St. Louis, MO, U.S.A. The stock solu-
tions of bradykinin, des-Arg
9-bradykinin, sarafotoxin 6b
and sarafotoxin 6c were prepared in 0.1% bovine serum
albumin. Nicotine, YM976, SP600125, MG624 and for-
skolin were dissolved in DMSO. Theophylline, hexam-
ethonium, 5-HT, carbachol and acetylcholine were
dissolved in distilled water, and indomethacin in 95%
ethanol. All agonists were serially diluted with physiolo-
gical saline prior to experiments.
Data analysis
All data were expressed as mean ± S.E.M. Agonist con-
centration-effect curve data from individual segments
were fitted to the Hill equation using an iterative, least-
squares method (GraphPad Prism 5, San Diego, CA, U.
S.A.) to provide estimates of maximal contraction (Emax)
and pEC50 (negative logarithm of the agonist concentra-
tion that produces half of its maximal effect). Contrac-
tile responses to agonists are all expressed in mN.
Concentration-effect curves obtained from myograph
studies were compared using two-way analysis of var-
iance (ANOVA) with Bonferroni’s post-test. Unpaired
student’s t-test with Welch’s correction was used when
two groups were compared. P ≤ 0.05 was considered to
be statistically significant.
Results
Effects of nicotine on kinin B1 and B2 receptor-mediated
airway contractions
In order to assess the time-course of nicotine effects on
the airway contraction, tracheal segments were organ-
cultured for 1, 2 or 4 days in the presence of nicotine
(10 μM) or vehicle. A tendency towards an increased
airway contractile response to des-Arg
9-bradykinin and
bradykinin was seen already after 2 days of nicotine
treatment and this increase reached statistical signifi-
cance at day 4 (Fig. 1A-F, Table 1).
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Page 4 of 17Figure 1 Nicotine-induced effects on kinin receptor-mediated airway contractions.T r a c h e a ls e g m e n t sw e r ec u l t u r e df o r1d a y( A ,B ) ,2
days (C, D) or 4 days (E, F) in presence of vehicle (Control, 0.1% DMSO) or nicotine (Nic, 1 or 10 μM). Contractions were induced by des-Arg
9-
bradykinin (D-A-BK; A, C, E) or bradykinin (BK; B, D, F). Each data point is derived from 15-22 experiments and data is presented as mean ± S.E.M.
Statistical analysis was performed using two-way ANOVA with Bonferroni’s post-test. Control vs Nic. * P < 0.05; ** P < 0.01; *** P < 0.001.
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tracheal segments after 4-day culture. A lower nicotine
concentration (1 μM) did not significantly increase con-
tractile responses to des-Arg
9-bradykinin and bradyki-
nin. Culture with 10 μM of nicotine significantly
increased the Emax for both agonists. Although a ten-
dency towards an increased pEC50 can be seen, it did
not reach statistical significance (Fig. 1E-F, Table 1).
Nicotine (1 or 10 μM) treatment for 1, 2 or 4 days did
not affect the contractile response mediated by 5-HT,
cholinergic (Table 2) or endothelin receptors (Table 3).
Effects of nicotine on kinin B1 and B2 receptor-mediated
airway relaxations
Bradykinin and des-Arg
9-bradykinin can also produce
relaxant effects on preconstricted tracheal segments. This
relaxation is dependent on the airway epithelium as well
as on COX activity and EP receptors [21]. Pretreatment of
the segments with COX-inhibitor indomethacin for 30
min makes it possible to study receptor-mediated contrac-
tions, as described in Figure 1. Absence of indomethacin
allows characterization of kinin-induced relaxations suc-
ceeding pre-contraction of the segments with carbachol (1
μM). After 4 days of organ culture with nicotine (10 μM)
or vehicle (0.1% DMSO), neither B1 nor B2 receptor-
mediated relaxations are affected by nicotine (Fig. 2A-B).
Effects of nicotinic receptor antagonists on nicotine-
enhanced kinin B1 and B2 receptor-mediated airway
contractions
Neuronal nicotinic acetylcholine receptors can very
roughly be divided into two groups: a-bungarotoxin-sensi-
tive receptors that contain the a7 subunit and a-bungaro-
toxin-insensitive receptors. MG624 is a specific antagonist
for the a7 subunit [24], while hexamethonium inhibits a-
bungarotoxin-insensitive receptors [25]. In order to find
out if the observed nicotine effects on B1 and B2 receptor-
mediated contractions are mediated through nicotinic
receptors, tracheal segments were cultured with 10 μM
nicotine in combination with either MG624 (100 nM) or
hexamethonium (1 or 10 μM). Results show that MG624
completely revoked the enhanced contractions caused by
nicotine for both kinin receptors without altering the con-
tractile response in the control group (0.1% DMSO) at all
( F i g .3 A - B ) .I na n a l o g y ,h e x a m e t h o n i u m( 1 0μM) also
depressed the nicotine-enhanced kinin effects (Fig. 3C-D).
Applying the same hexamethonium concentration to the
DMSO-treated control segments did not cause a decrease
in contractile responses for B1 and B2 receptors, but rather
a weak tendency towards increased contraction (Fig. 3E-
F). Altogether, the results suggest a clear involvement of
neuronal nicotinic receptors in nicotine-induced effects on
B1 and B2 receptor-mediated contractions in airways.
Table 1 Effects of nicotine on des-Arg
9-bradykinin- and bradykinin-induced airway contractions
Incubation time Nicotine (μM) des-Arg
9-bradykinin Bradykinin
n Emax (mN) pEC50 n Emax (mN) pEC50
Day 1 0 (Ctrl) 17 1.21 ± 0.19 6.49 ± 0.12 15 0.99 ± 0.18 5.81 ± 0.13
10 18 1.33 ± 0.17 6.52 ± 0.11 16 1.29 ± 0.16 5.79 ± 0.18
Day 2 0 (Ctrl) 16 1.47 ± 0.19 6.56 ± 0.14 17 1.51 ± 0.23 6.15 ± 0.27
10 16 1.52 ± 0.19 6.94 ± 0.13 17 1.86 ± 0.19 6.75 ± 0.35
Day 4 0 (Ctrl) 18 1.16 ± 0.13 6.96 ± 0.19 21 1.40 ± 0.20 6.72 ± 0.38
1 16 1.89 ± 0.26 6.28 ± 0.50 19 2.10 ± 0.34 6.57 ± 0.36
10 21 2.04 ± 0.25 ** 7.20 ± 0.20 22 2.18 ± 0.26 * 7.30 ± 0.25
Tracheal segments were cultured for 1, 2 or 4 days in presence of vehicle (0.1% DMSO, Ctrl) or nicotine (1 or 10 μM). Emax and pEC50 for des-Arg
9-bradykinin and
bradykinin are presented as mean ± S.E.M. Statistical analysis was performed using unpaired student’s t-test with Welch’s correction. Nicotine vs. Ctrl (DMSO). * P
< 0.05, **P < 0.01. n = number of experiments performed.
Table 2 Effects of nicotine on 5-HT- and acetylcholine-induced airway contractions
Incubation time Nicotine (μM) 5-HT Acetylcholine
n Emax (mN) pEC50 n Emax (mN) pEC50
Day 1 0 (Ctrl) 9 1.87 ± 0.32 6.47 ± 0.13 8 5.81 ± 0.74 6.51 ± 0.12
10 10 1.97 ± 0.26 6.45 ± 0.10 8 6.20 ± 0.62 6.46 ± 0.07
Day 2 0 (Ctrl) 11 2.01 ± 0.29 6.83 ± 0.09 8 6.45 ± 0.70 6.57 ± 0.06
10 12 1.99 ± 0.31 6.87 ± 0.09 8 5.95 ± 0.73 6.56 ± 0.10
Day 4 0 (Ctrl) 10 2.01 ± 0.23 6.98 ± 0.08 6 6.04 ± 1.05 6.43 ± 0.07
1 9 1.89 ± 0.28 7.00 ± 0.13 6 5.24 ± 0.64 6.56 ± 0.12
10 8 1.88 ± 0.18 6.89 ± 0.18 6 5.70 ± 0.49 6.61 ± 0.11
Tracheal segments were cultured for 1, 2 or 4 days in presence of vehicle (0.1% DMSO, Ctrl) or nicotine (1 or 10 μM). Emax and pEC50 for 5-HT and acetylcholine
are presented as mean ± S.E.M. Statistical analysis was performed using unpaired student’s t-test with Welch’s correction. Nicotine vs Ctrl (DMSO). No significant
differences were found between the two groups. n = number of experiments performed.
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mRNA and protein expressions
The relative amount of mRNA for kinin B1 and B2
receptors was quantified by real-time PCR. Four days of
o r g a nc u l t u r ei nt h ep r e s e n c eo fn i c o t i n e( 1 0μM)
increased the mRNA expression for both receptors,
compared to control (Fig. 4A). The corresponding pro-
tein expression was examined using confocal-micro-
scopy-based immunohistochemistry. An increase in
kinin B1 (Fig. 5A-B) and B2 (Fig. 5C-D) receptor protein
expressions were seen in both the airway epithelial and
smooth muscle cells (Fig. 5E-F). In the control seg-
ments, the expression of B1 receptors is higher in the
epithelial cells compared to the smooth muscle cells;
while after nicotine treatment, the increase in B1 recep-
tor protein expression was more prominent in the
smooth muscle cells than in the epithelial cells (Fig. 5E).
For B2 receptors, their expressions in the control
segments are similar between epithelial cells and smooth
muscle cells; while after nicotine treatment, B2 receptors
are expressed more in the epithelial cells than the
smooth muscle cells (Fig. 5F).
Intracellular MAPK signal transduction mechanism studies
To explore the underlying intracellular signal transduc-
tion mechanisms behind the reported nicotine effects on
airway kinin receptors, the activation (phosphorylation)
of JNK, ERK1/2 and p38 signal molecules were studied
with confocal-microscopy-based immunohistochemistry.
After 4 days of organ culture with nicotine (10 μM), an
activation of JNK was observed in the airway epithelial
and in smooth muscle cells compared to control (Fig.
6A-B). This increase was most marked in the smooth
muscle cells (Fig. 6G). In the control segments, the
expression of phosphorylated ERK1/2 (Fig. 6C) and p38
(Fig. 6E) was more abundant in the tracheal epithelium
Table 3 Effects of nicotine on endothelin receptor-mediated airway contractions
Incubation time Nicotine (μM) ETA ETB
n Emax (mN) pEC50 n Emax (mN) pEC50
Day 1 0 (Ctrl) 10 3.61 ± 0.40 7.52 ± 0.14 9 3.49 ± 0.68 8.00 ± 0.13
10 10 3.40 ± 0.33 7.50 ± 0.07 10 3.52 ± 0.53 7.89 ± 0.07
Day 2 0 (Ctrl) 4 3.74 ± 0.87 7.40 ± 0.20 4 3.33 ± 0.34 8.24 ± 0.13
10 4 4.22 ± 0.85 7.52 ± 0.11 4 3.15 ± 0.60 8.00 ± 0.13
Day 4 0 (Ctrl) 9 4.32 ± 0.71 7.81 ± 0.10 9 4.31 ± 0.73 8.05 ± 0.09
1 9 4.13 ± 0.42 7.74 ± 0.07 9 4.03 ± 0.46 8.17 ± 0.13
10 8 4.67 ± 0.37 7.86 ± 0.10 8 4.47 ± 0.38 8.18 ± 0.12
Tracheal segments were cultured for 1, 2 or 4 days in presence of vehicle (0.1% DMSO, Ctrl) or nicotine (1 or 10 μM). ETA: endothelin receptor type A; ETB:
endothelin receptor type B. Responses of ETB receptors were tested with the selective ETB agonist sarafotoxin 6c, while responses to ETA receptors were tested
with the non-selective ET-receptor agonist sarafotoxin 6b after the desensitization of ETB receptors [39]. Emax and pEC50 are presented as mean ± S.E.M. Statistical
analysis was performed using unpaired student’s t-test with Welch’s correction. Nicotine vs Ctrl (DMSO). No significant differences were found between the two
groups. n = number of experiments performed.
Figure 2 Nicotine-induced effects on kinin receptor-mediated airway relaxations. Tracheal segments were cultured for 4 days in presence
of vehicle (Control, 0.1% DMSO) or nicotine (Nic, 10 μM). Relaxations were induced by des-Arg
9-bradykinin (D-A-BK; A) or bradykinin (BK; B) after
pre-constriction with carbachol (1 μM). Each data point is derived from 6-8 experiments and data is presented as mean ± S.E.M. Statistical
analysis was performed using two-way ANOVA with Bonferroni’s post-test. Control vs Nic. No significant differences were found between the
two groups.
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Page 7 of 17Figure 3 Effects of neuronal nicotinic receptor antagonists on nicotine-enhanced kinin B1 and B2 receptor-mediated contractions.
Tracheal segments were cultured for 4 days in presence of vehicle (DMSO, 0.1%) or nicotine (Nic, 10 μM) with/without neuronal nicotinic
receptor antagonist MG624 (MG, 100 nM, A, B) or hexamethonium (Hexa, 1 or 10 μM, C-F). Contractions were induced by des-Arg
9-bradykinin
(D-A-BK; A, C, E) or bradykinin (BK; B, D, F). Each data point is derived from 3-6 experiments and data is presented as mean ± S.E.M. Statistical
analysis was performed using two-way ANOVA with Bonferroni’s post-test. Nic vs Nic+MG/Hexa (A-D), DMSO vs DMSO+MG/Hexa (A, B, E, F).
* P < 0.05; ** P < 0.01; *** P < 0.001.
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Page 8 of 17than smooth muscle cells (Fig. 6H-I). However, in con-
trast to JNK, no significant differences in ERK1/2 (Fig.
6 C ,D ,H )o rp 3 8( F i g .6 E ,F ,I )a c t i v i t i e sw e r ef o u n d
between the specimen treated with nicotine (10 μM) for
4 days and the control (DMSO).
In order to link the activation of JNK to nicotine-
induced up-regulation of kinin B1 and B2 receptors, a
specific JNK inhibitor SP600125 (10 μM) was added
together with nicotine during the 4 days of culture. Phar-
macological inhibition of JNK abolished the nicotine-
enhanced kinin B1 and B2 receptor-mediated contrac-
tions (Fig. 7A-B) and decreased the nicotine-enhanced
kinin B1 and B2 receptor mRNA expressions (Fig. 4B).
Effects of dexamethasone and PDE inhibition
Dexamethasone is a potent glucocorticoid and well-
known anti-inflammatory drug. Administration of dexa-
methasone (1 μM) together with nicotine in the organ
culture for 4 days almost completely abolished the nico-
tine-enhanced airway contractions to both des-Arg
9-bra-
dykinin (Fig. 7C) and bradykinin (Fig. 7D).
To explore the role of PDE in nicotine-enhanced con-
tractile response to the kinins, PDE inhibitors YM976
and theophylline were applied. Theophylline is a non-
selective PDE inhibitor, while YM976 is a specific inhibi-
tor for PDE4. The latter PDE subtype is specific for
cAMP and thought to be of importance for asthmatic
inflammation [26]. After 4 days of treatment with the
PDE inhibitors, YM976 concentration-dependently atte-
nuated nicotine up-regulated B1 receptor-mediated con-
tractions (Fig. 8C), whereas the dose-relation was less
obvious for contractions mediated via B2 receptors (Fig.
8D). Contractile responses of the control (DMSO) seg-
ments were unaffected by YM976 (Fig. 8E-F). The
decrease in receptor-mediated contractions is paralleled
with a significant decrease in nicotine-enhanced kinin
B1 and B2 receptor mRNA expression shown by real-
time PCR (Fig. 4B). Theophylline exhibited similar
effects as YM976, effectively attenuating both B1 and B2
receptor-mediated airway contractions. The theophylline
effect is clearly concentration-dependent (Fig. 8A-B).
Effects of cAMP
Forskolin is an adenylyl-cyclase activator and raises the
level of intracellular cAMP. YM976 inhibits PDE4, the
enzyme responsible for the breakdown of cAMP, which
in turn also causes an increase in intracellular cAMP
levels. To test whether elevation of intracellular cAMP
levels is responsible for the PDE inhibitors’ ability to
attenuate nicotine-enhanced B1 and B2 receptor-
mediated contraction, we treated the segments with for-
skolin (10 μM) for 4 days in the absence or presence of
nicotine (10 μM). Results show that forskolin suppresses
contractions induced by both bradykinin and des-Arg
9-
bradykinin, and this is regardless of the presence or
absence of nicotine (Fig. 9A-B).
Discussion
Cigarette smoke is associated with chronic airway
inflammation, AHR, increased asthma severity and to a
certain degree, asthma development in children [1-7].
Chronic exposure to tobacco smoke increases AHR to
bradykinin in vivo [8]. The presented study demon-
strated for the first time that long-term exposure (for 4
days) of mouse tracheal segments to nicotine causes a
concentration-dependent increase of kinin B1 and B2
receptor-mediated airway contractions. Since B1 and B2
receptor-mediated relaxation remained unaffected, the
Figure 4 Kinin B1 (B1R) and B2 (B2R) receptor mRNA
expression. Tracheal segments were cultured for 4 days in
presence of vehicle (DMSO, control) or nicotine (Nic, 10 μM) (A). JNK
inhibitor SP600125 or PDE4 inhibitor YM976 was added to 4-day
culture with nicotine (10 μM) (B). Each data point is derived from
3-6 experiments and data is presented as mean ± S.E.M. Statistical
analysis was performed using unpaired student’s t-test with Welch’s
correction. Control vs Nic (A); Nic vs Nic+SP600125/YM976 (B).
** P < 0.01; *** P < 0.001.
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Page 9 of 17resulting netto effect is an increase in contraction.
Short-term nicotine exposure (for 1 - 2 days) induced
no significant effects. Neither did nicotine treatment
affect airway contractions mediated by 5-HT, cholinergic
or endothelin receptors. The increase in maximal con-
traction, without significant change of pEC50,s e e na f t e r
4 days of nicotine treatment suggests an increase in
kinin receptor protein expression rather than alteration
of receptor sensitivity. This conclusion is further sup-
ported by the discovery of an up-regulated protein
expression for both B1 and B2 receptors using confocal
microscopy. In addition, real-time PCR reveals a parallel
increase in B1 and B2 receptor mRNA suggesting the
involvement of transcriptional mechanisms in nicotine’s
effects. The neuronal nicotinic receptor antagonists
MG624 and hexamethonium both abolish the nicotine-
enhanced kinin effect, signifying the participation of
nicotinic receptors in the start of the process. Further,
the intracellular cascade related to the kinin receptor
up-regulation seems to involve JNK- and PDE4-related
intracellular signal pathways.
Neuronal nicotinic receptors in non-neuronal cells have
been proposed to be mediators of tobacco toxicity since
they are considered to have a “hormone-like” function
[27]. Our results show that the neuronal nicotinic receptor
antagonists MG624 [24] and hexamethonium [25] both
Figure 5 Nicotine-induced effects on kinin B1 (B1R) and B2 (B2R) receptor protein expression. Tracheal segments were cultured for 4 days
in presence of vehicle (DMSO, A, C) or nicotine (Nic, 10 μM, B, D). The reference bar corresponds to 25 μm. The intensity of fluorescence was
semi-quantified using Image J software (E, F). Epi = epithelium; SMC = smooth muscle cells; and C = cartilage. Each data point is derived from 6
experiments. Two-tailed unpaired Student’s t-test with Welch’s correction was preformed. Control vs Nic. * P < 0.05; *** P < 0.001.
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Page 10 of 17Figure 6 Nicotine-induced effects on phosphorylated JNK (pJNK), ERK1/2 (pERK1/2) and p38 (p-p38) protein expression.T r a c h e a l
segments were cultured for 4 days in presence of vehicle (DMSO, A, C, E) or nicotine (Nic, 10 μM, B, D, F). The reference bar corresponds to 25
μm. The intensity of fluorescence was semi-quantified by Image J software (G, H, I). Epi = epithelium; SMC = smooth muscle cells; and
C = cartilage. Each data point is derived from 6 experiments. Two-tailed unpaired Student’s t-test with Welch’s correction was preformed. Control
vs Nic. ** P < 0.01; *** P < 0.001, N.S. = no significance.
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Page 11 of 17inhibit nicotine’s effects on the kinin receptor-mediated
contractions, without suppressing contractions in control
segments. In human smokers, nicotine is not only found
in blood plasma, but also in saliva and induced sputum.
The nicotine concentrations in saliva can be up to 8 μM
during “smoking days” [28] and 5 min after smoking a
cigarette, the induced sputum (not contaminated with sal-
iva) contains a surprising 34 μM of nicotine [29]. There-
fore, the lungs and bronchial surfaces of smokers might be
exposed to a much higher nicotine concentration than
that measured in the bloodstream. The concentration that
was demonstrated to cause a significant effect in the pre-
sent study was 10 μM. The same concentration has pre-
viously been shown to cause phosphorylation of the
MAPK p44/42, an effect that can be inhibited by nAChR
antagonists [30]. Similar nicotine concentrations is also
k n o w nt oi n d u c ea l t e r a t i o ni nt h eg e n e - e x p r e s s i o no f
macrophage-like human cell line [31].
Many GPCRs are involved in the regulation of the
contractile state of airway smooth muscle, including 5-
HT, bradykinin, endothelin (type A and type B) and M3
muscarinic acetylcholine receptors. Bradykinin, endothe-
lin and M3 muscarinic receptors are Gq-coupled while
5-HT receptors are Gi-coupled [18]. The presented
results show that nicotine up-regulated kinin B1 and B2
receptor-mediated airway contractions, leaving 5-HT,
cholinergic and endothelin receptor-mediated contrac-
tions completely unaffected. This suggests that nicotine
acts on specific targets within the airways. Thus, the
effects observed are neither the result of a general
hyperresponsiveness nor due to alteration of down-
stream G-protein signaling processes. This idea is
further strengthen by our findings of a simultaneous up-
regulation of receptor function, mRNA and protein
expression. It is known that bradykinin acts as a potent
bronchoconstrictor in asthmatic patients, but has no
Figure 7 Effects of JNK inhibitor SP600125 (10 μM) and dexamethasone (Dex, 1 μM) on nicotine-enhanced des-Arg
9-bradykinin- (A, C)
and bradykinin- (B, D) induced contractions. Tracheal segments were cultured for 4 days in presence of nicotine (Nic, 10 μM) together with
vehicle or SP600125 (A, B) or dexamethasone (C, D). Each data point is derived from 10-12 experiments.
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Page 12 of 17Figure 8 Effects of YM976 (C, D, E, F) and theophylline (A, B) on nicotine-enhanced des-Arg
9-bradykinin- (A, C, E) and bradykinin-
(B, D, F) induced contractions. Tracheal segments were cultured for 4 days in absence (E, F) or presence (A-D) of nicotine (Nic, 10 μM)
together with vehicle, YM976 (YM, 1 μM or 10 nM) or theophylline (TEO, 10 or 100 μM). Each data point is derived from 4-17 experiments and
presented as mean ± S.E.M. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post-test. Nic vs Nic+TEO (A, B); Nic
+vehicle vs Nic+YM (C, D); DMSO vs DMSO+YM (E, F). * P < 0.05; ** P < 0.01; *** P < 0.001.
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Page 13 of 17effect in normal individuals [21]. Many studies have also
demonstrated a strong link between allergic inflamma-
tion, AHR and bradykinin [32-34]. Further, polymorph-
ism in the B2 receptor gene has been found to be
associated with asthma prior to the age of 4 [35]. Our
results support the importance of bradykinin in AHR
and reveal a special role for bradykinin in nicotine- and/
or tobacco smoke-induced AHR.
Stimulation of the kinin receptors can cause both
bronchoconstriction and epithelium-dependent relaxations
in the airways. It is interesting to note that though kinin
receptor protein expression was increased both on the
epithelium and smooth muscle, bradykinin- and des-Arg
9-
bradykinin-induced relaxations were unaffected. This
might be due to involvement of different pathways. Stimu-
lation of kinin B1 and B2 receptors on the airway smooth
muscle directly activates the inositol 1,4,5-trisphosphate
(IP3) pathway increasing intracellular Ca
2+ levels which
subsequently activates the cellular contractile machinery
[18]. Kinin receptor-mediated relaxation, on the other
hand, is epithelium-dependent. Bradykinin and des-Arg
9-
bradykinin activate COX and stimulate the release of
PGE2 from airway epithelial cells which induce airway
relaxation through EP receptor activation [21]. Therefore,
kinin receptor-mediated relaxations are strongly depen-
dent on intact epithelial functions. Nicotine can damage
airway epithelial cells with changes in ionic relations and
cause submucosal edema as shown with electron micro-
scopy examination of nicotine-treated rat trachea [36].
This might impair the relaxant functions of airways, disre-
garding the abundance of kinin receptors.
JNK, ERK1/2 and p38 are the classical members of the
MAPK family. They are known to play key roles in the
regulation of gene expressions. A recent study with
human lung macrophages revealed an increase in MAPK
phosphorylation and activation of the MAPK/AP-1 path-
way caused by cigarette smoke [37]. In another study of
human bronchial epithelial cells, ERK1/2, JNK, but not
p38 was strongly activated after treatment with nicotine
[13]. A special role of JNK in the pathogenesis of asthma
has also been implicated [38]. In the present study, nico-
tine induced activation of JNK, but not ERK1/2 and p38.
SP600125 is a small molecular inhibitor for JNK. At the
concentration of 10 μM, SP600125 selectively inhibits the
phosphorylation of JNK, but not ERK1/2 or p38 in ves-
sels [39]. Our results show that SP600125 abolished the
nicotine-enhanced kinin receptor-mediated contractions
and the receptor mRNA expression. These results are
well in line with a previous study which has demon-
strated that SP600125 exhibits powerful inhibitory effect
on TNF-a induced up-regulation of kinin B1 and B2
receptors in airways [20]. Both bradykinin and des-Arg
9-
bradykinin elicits only negligible contractile responses in
fresh segments and the culture procedure per se causes
an up-regulation of the kinin receptors [20]. The B1 and
B2 receptor-mediated contractions were nearly comple-
tely abolished by SP600125, suppressing the contractile
response to a level similar to that seen in fresh segments
[20]. This suggests that both nicotine and the organ cul-
ture procedure induce activation of the same intracellular
pathway i.e. the MAPK JNK pathway. The increase in B1
and B2 receptor mRNA and protein expression after
organ culture with nicotine strengthens the evidence for
an alteration at the receptor level rather than a down-
stream process. Furthermore, SP600125 up to 30 μM
causes no alteration in carbachol-elicited contractile
Figure 9 Effects of forskolin on nicotine-enhanced des-Arg
9-bradykinin- (A) and bradykinin- (B) induced contractions.T r a c h e a l
segments were cultured for 4 days in absence (DMSO) or presence of nicotine (Nic, 10 μM) together with vehicle or forskolin (FO, 10 μM). Each
data point is derived from 3-4 experiments and presented as mean ± S.E.M.
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Page 14 of 17responses [20], which excludes the possibility of toxic
effects of SP600125 on the contractile machinery of the
tracheal segments.
Dexamethasone reduces inflammation and hyperreac-
tivity in asthmatic airways [40,41], inhibits kinin recep-
tor expression in cultured human airway fibroblast and
smooth muscle cells [42,43]. It also suppress both TNF-
a- and organ culture-induced kinin receptor expression
in airway smooth muscle [22]. In line with this, the pre-
sent data demonstrates that dexamethasone inhibited
nicotine-enhanced kinin B1 and B2 receptor-mediated
effects in murine airways. It is interesting to note that
the effect of dexamethasone appears to be very similar
to those of SP600125. Dexamethasone is classically
thought to exert its effects via the inhibition of the pro-
inflammatory transcription factors activator protein-1
(AP-1) and NF-B [44]. The JNK cascade has long been
related to the transcription factor NF-B[ 4 5 ]a n di t s
ability to bind to AP-1 and form the transcription com-
plex c-JUN/AP-1 is well-known. Nicotine has been
reported to activate NF-B through phosphorylation of
JNK [46]. In addition, cigarette smoke can activate AP-1
also via the MAPK/JNK pathway [37,47]. It is therefore
tempting to assume that the presently seen effects of
dexamethasone are related to inhibition of transcription
factor activation downstream of the JNK pathway. How-
ever, it has been recently shown that dexamethasone’s
intracellular actions are much more complex. They
include both inhibition of the upstream negative regula-
tor of JNK and p38 MAPKs called MAP kinase phos-
phatase-1 [48] and post-transcriptional/translational
regulation of gene expressions [42,49].
YM976 is a selective PDE4 inhibitor shown to possess
powerful anti-inflammatory and direct broncho-relaxant
effects in combination with low emetogenicity [26]. The
latter is a common problem with older PDE4 inhibitors.
Theophylline is a classical, archetypal, non-specific PDE
inhibitor. Both drugs attenuated the enhancement caused
by nicotine on kinin B1 and B2 receptor-mediated airway
contractions. Moreover, YM976 also suppresses nicotine-
enhanced kinin receptor mRNA expression. PDE4 is
expressed in airway smooth muscle cells and increases
intracellular concentration of the second messenger
cAMP [50]. Inhibition of PDE4 suppresses endotoxin-
induced airway inflammation and hyperreactivity [51],
inhibits reactive oxygen species production, cell adhesion
molecule expression and the release of cytokines from
activated T-helper cells, airway epithelial cells, basophils,
monocytes and macrophages [52]. The mechanisms
behind the effects of PDE inhibitors might be related to
changes in cAMP-dependent inflammatory pathways via a
reduction of TNF-a-induced expression of RANTES, che-
mokines and eotaxin in the airway smooth muscle cells
[53]. When intracellular cAMP levels were directly raised
with the adenylyl cylase activator forskolin, we observed
effects similar to those of PDE-inhibitors. The downstream
protein kinase PKA has also been reported to be involved
in cytokine-stimulated up-regulation of kinin B2 receptors
[42]. However, inhibition of PDE4 produces a specific
depression of nicotine’s effects without altering control,
while forskolin depresses contractile responses in both the
nicotine and control group. This suggests that the nico-
tine-induced changes might be PDE4-specific. PDE4 is
dependent on cAMP to produce a cellular response.
Hence, the ability to enhance intracellular cAMP levels,
although disparate for both YM976 and theophylline,
might be responsible for their suppression of nicotine-
enhanced kinin receptor-mediated contractions.
Our results show the simultaneous involvement of
both JNK and PDE4/cAMP-mediated pathway in nico-
tine’s effects on kinin receptors. Supporting this, there
have been many reports on the “cross-talk” between
cAMP and JNK pathway. cAMP has the ability to inhibit
JNK activation in human airway smooth muscle cells
[54], and in rat renal mesangial cells. Forskolin inhibits
MAPK [55]. Activation of ERK5 and the subsequent
transcription of c-JUN, but not ERK1/2, can be blocked
by cAMP through PKA [17].
To conclude, nicotine has been shown to have the abil-
ity to enhance bradykinin- and des-Arg
9-bradykinin-
induced airway contractions without affecting their
relaxations. The nicotine effect is mediated by activation
of airway neuronal nicotinic receptors which results in a
transcriptional up-regulation of kinin B1 and B2 recep-
tors. The whole process depends on the activation of
JNK- and PDE4-related intracellular signal pathways
Thus, our findings might provide new therapeutic targets
for future treatment of tobacco smoke-associated AHR.
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